GlobeNewswire·Nov 9, 2026, 4:01 PM ET

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

SIGA Technologies announced the retirement of Dennis Hruby, Ph.D., effective November 9, 2026, concluding over 30 years with the firm.
Dr. Hruby joined SIGA in 1996 as a senior scientific advisor, became Vice President of Research in 1997, and served as Chief Scientific Officer since 2000.
He led the development of tecovirimat (TPOXX), which received U.S. FDA approval for oral formulation in 2018 and intravenous formulation in 2022.
TPOXX gained regulatory approval in Canada, the European Union, the United Kingdom, and Japan, becoming the first antiviral therapeutic approved for smallpox treatment.
The drug has been sold to more than 30 countries to protect against naturally occurring, accidental, or intentional infectious disease threats.
CEO Diem Nguyen praised Dr. Hruby's scientific rigor, vision, and instrumental role in strengthening national smallpox preparedness.
Dr. Hruby expressed pride in leaving an approved, stockpiled, and ready antiviral treatment for smallpox to a strong team.
Following his retirement, Dr. Hruby will continue to support SIGA in an advisory capacity.